Literature DB >> 24701998

Impact on prognosis of periprocedural bleeding after TAVI: mid-term follow-up of a multicenter prospective study.

Claudio Moretti1, Maurizio D'Amico, Fabrizio D'Ascenzo, Chiara Colaci, Stefano Salizzoni, Corrado Tamburino, Patrizia Presbitero, Sebastiano Marra, Imad Sheiban, Fiorenzo Gaita.   

Abstract

AIMS: Impact of periprocedural bleeding after transcatheter aortic valve implantation (TAVI) over mid-term prognosis remains still unclear.
METHODS: Consecutive patients who underwent TAVI from May 2008 to July 2012 were prospectively included and stratified according to life-threatening (LT) and major bleeding (MB). Mid-term all-cause death was the primary end-point, and 30-day death, vascular complications, stroke, and acute kidney injury the secondary ones. All end-points were adjudicated according to VARC.
RESULTS: Seven hundred fourteen patients with an average age of 81.9 ± 5.8 years were included. 130 (18%) patients suffered a LT, 112 (16%) a MB. A preprocedural GFR <30 ml/min and increasing diameter of sheaths were independent predictors of LT or MB, while transfemoral approach showed a protective effect (OR 0.42; CI: 0.26-0.68; P = 0.035). At 30 days LT (OR 3.3; CI: 1.1-9.7; P = 0.0026) and MB (OR 3.5; CI: 1.4-8.6; P = 0.007) bleeding along with GFR < 30 ml/min (OR 2.3; CI: 1.1-5.5; P = 0.04) were independent predictors of death, while bleeding did not impact survival on mid term (OR 0.9; CI: 0.47-1.7; P = 0.78; all CI 95%).
CONCLUSION: Periprocedural bleeding after TAVI was frequent and associated with an increased mortality after 30 days but not after mid-term follow-up. A preprocedural GFR < 30 ml/min was the most important predictor of bleeding, enabling risk stratification and choice of approach for these patients.
© 2014, Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24701998     DOI: 10.1111/joic.12115

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  8 in total

Review 1.  Percutaneous management of vascular access in transfemoral transcatheter aortic valve implantation.

Authors:  Ilaria Dato; Francesco Burzotta; Carlo Trani; Filippo Crea; Gian Paolo Ussia
Journal:  World J Cardiol       Date:  2014-08-26

2.  Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience.

Authors:  Manolis Vavuranakis; Konstantinos Kalogeras; Dimitrios Vrachatis; Maria Kariori; Carmen Moldovan; Evelina Mpei; Maria Lavda; Angelos-Michail Kolokathis; Gerasimos Siasos; Dimitrios Tousoulis
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

3.  Choice of desflurane or propofol for the maintenance of general anesthesia does not affect the risk of periprocedural myocardial damage in patients undergoing transfemoral transcatheter aortic valve implantation.

Authors:  Kenta Okitsu; Takeshi Iritakenishi; Tatsuyuki Imada; Michioki Kuri; Sho Carl Shibata; Yuji Fujino
Journal:  J Anesth       Date:  2017-12-06       Impact factor: 2.078

Review 4.  Impact of renal dysfunction on mid-term outcome after transcatheter aortic valve implantation: a systematic review and meta-analysis.

Authors:  Chi Chen; Zhen-Gang Zhao; Yan-Biao Liao; Yong Peng; Qing-Tao Meng; Hua Chai; Qiao Li; Xiao-Lin Luo; Wei Liu; Chen Zhang; Mao Chen; De-Jia Huang
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

5.  Network meta-analysis on the comparative effectiveness and safety of transcatheter aortic valve implantation with CoreValve or Sapien devices versus surgical replacement.

Authors:  G Biondi-Zoccai; M Peruzzi; A Abbate; Z M Gertz; U Benedetto; E Tonelli; F D'Ascenzo; A Giordano; P Agostoni; G Frati
Journal:  Heart Lung Vessel       Date:  2014

Review 6.  Antithrombotic therapy in TAVI.

Authors:  Manolis Vavuranakis; Konstantinos Kalogeras; Angelos Michail Kolokathis; Dimitrios Vrachatis; Nikolaos Magkoutis; Gerasimos Siasos; Euaggelos Oikonomou; Maria Kariori; Theodoros Papaioannou; Maria Lavda; Carmen Moldovan; Ourania Katsarou; Dimitrios Tousoulis
Journal:  J Geriatr Cardiol       Date:  2018-01       Impact factor: 3.327

7.  Predictors of early mortality after transcatheter aortic valve implantation.

Authors:  Didrik Kjønås; Gry Dahle; Henrik Schirmer; Siri Malm; Jo Eidet; Lars Aaberge; Terje Steigen; Svend Aakhus; Rolf Busund; Assami Rösner
Journal:  Open Heart       Date:  2019-04-23

8.  Prevalence of Posttranscatheter Aortic Valve Implantation Vascular Complications in Real Life.

Authors:  Anthony Matta; Ronan Canitrot; Vanessa Nader; Frederic Bouisset; Thibault Lhermusier; Francisco Campelo-Parada; Etienne Grunenwald; Bertrand Marcheix; Meyer Elbaz; Didier Carrie; Jerome Roncalli
Journal:  J Interv Cardiol       Date:  2021-10-12       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.